Non-Peptide CGRP Receptor Antagonists for Migraine Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CGRP-mediated disorders, such as migraine and cluster headache, are inadequate in effectively addressing the underlying vasodilation and neuronal sensitization mechanisms.
Innovation Solution
Development of compounds that act as CGRP receptor antagonists, specifically targeting the CGRP receptors to inhibit the biological actions of CGRP, thereby reducing vasodilation and neuronal sensitization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for CGRP-mediated disorders are used, then they provide some therapeutic effect, but they fail to effectively address the underlying vasodilation and neuronal sensitization mechanisms
Solution Approach 1:
The patent introduces a non-peptide CGRP receptor antagonist as an intermediary substance that blocks the interaction between CGRP and its receptor. This mediator prevents CGRP from binding to and activating its receptor, thereby interrupting the pathological signaling cascade without requiring to replace the entire treatment system
Solution Approach 2:
The invention changes the chemical parameter of the antagonist from peptide-based to non-peptide small molecule structure. This parameter change improves pharmacokinetic properties, brain penetration, and metabolic stability while maintaining CGRP receptor blocking activity, thereby enhancing overall therapeutic effectiveness
2Object-affected harmful factors
If CGRP is released and binds to receptors, then vasodilation occurs which is the major source of headache pain, but this vasodilation effect is the harmful mechanism that needs to be blocked
Solution Approach 1:
The non-peptide CGRP receptor antagonist is administered before or during the migraine attack to preemptively block CGRP receptor binding. This preliminary anti-action prevents CGRP from initiating the vasodilation cascade, stopping the harmful sequence before it can generate significant headache pain
Solution Approach 2:
The patent converts the harmful vasodilation effect into a beneficial therapeutic outcome by using the same CGRP receptor pathway. The antagonist blocks the receptor to prevent pathological vasodilation, thereby transforming the understanding of CGRP's role from harmful to beneficial when targeted pharmacologically
3Object-affected harmful factors
If trigeminal neurons are sensitized by CGRP-mediated vasodilation, then neuronal sensitization occurs leading to associated symptoms, but this sensitization is the harmful mechanism that amplifies pain
Solution Approach 1:
The CGRP receptor antagonist is administered to perform preliminary action by blocking CGRP receptor activation before neuronal sensitization can occur. This prevents the initial vasodilation and inflammatory signaling that would otherwise sensitize trigeminal neurons, thereby preventing the amplification of pain symptoms
Data Source
AI summary
The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.